STOCK TITAN

[Form 4] Soligenix, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Form 4 filing reveals that Anthony Gregg Lapointe, Director of Soligenix, received a stock option grant on June 20, 2025. The derivative securities transaction details include:

  • Granted 17,647 stock options to purchase common stock
  • Exercise price set at $1.70 per share
  • Options expire on June 20, 2035
  • Vesting schedule occurs in four equal installments: - September 20, 2025 - December 20, 2025 - March 20, 2026 - June 20, 2026

This grant represents standard director compensation and indicates continued board engagement. The 10-year option term provides long-term alignment with shareholder interests.

La comunicazione del modulo 4 rivela che Anthony Gregg Lapointe, Direttore di Soligenix, ha ricevuto una concessione di stock option il 20 giugno 2025. I dettagli della transazione sui titoli derivati includono:

  • Concessione di 17.647 stock option per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 1,70 $ per azione
  • Le opzioni scadono il 20 giugno 2035
  • Il piano di maturazione avviene in quattro rate uguali: - 20 settembre 2025 - 20 dicembre 2025 - 20 marzo 2026 - 20 giugno 2026

Questa concessione rappresenta una compensazione standard per i direttori e indica un continuo impegno nel consiglio di amministrazione. Il termine decennale delle opzioni assicura un allineamento a lungo termine con gli interessi degli azionisti.

La presentación del Formulario 4 revela que Anthony Gregg Lapointe, Director de Soligenix, recibió una concesión de opciones sobre acciones el 20 de junio de 2025. Los detalles de la transacción con valores derivados incluyen:

  • Otorgamiento de 17,647 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $1.70 por acción
  • Las opciones expiran el 20 de junio de 2035
  • El calendario de adquisición se realiza en cuatro cuotas iguales: - 20 de septiembre de 2025 - 20 de diciembre de 2025 - 20 de marzo de 2026 - 20 de junio de 2026

Esta concesión representa una compensación estándar para directores e indica un compromiso continuo con el consejo. El plazo de 10 años de las opciones proporciona una alineación a largo plazo con los intereses de los accionistas.

Form 4 제출서에 따르면 Anthony Gregg Lapointe 솔리제닉스 이사가 2025년 6월 20일에 스톡옵션을 부여받았습니다. 파생증권 거래 내역은 다음과 같습니다:

  • 17,647주의 보통주 매수 옵션 부여
  • 행사가격은 주당 $1.70
  • 옵션 만료일은 2035년 6월 20일
  • 옵션 권리 확정은 4회에 걸쳐 동일한 비율로 이루어짐: - 2025년 9월 20일 - 2025년 12월 20일 - 2026년 3월 20일 - 2026년 6월 20일

이번 부여는 이사 보상으로 일반적인 수준이며, 이사회 참여가 지속됨을 나타냅니다. 10년 만기 옵션은 주주 이익과 장기적으로 일치하도록 설계되었습니다.

Le dépôt du formulaire 4 révèle que Anthony Gregg Lapointe, administrateur de Soligenix, a reçu une attribution d'options d'achat d'actions le 20 juin 2025. Les détails de la transaction sur titres dérivés sont les suivants :

  • Attribution de 17 647 options d'achat pour acquérir des actions ordinaires
  • Prix d'exercice fixé à 1,70 $ par action
  • Les options expirent le 20 juin 2035
  • Le calendrier d'acquisition s'effectue en quatre versements égaux : - 20 septembre 2025 - 20 décembre 2025 - 20 mars 2026 - 20 juin 2026

Cette attribution représente une rémunération standard pour les administrateurs et témoigne d'un engagement continu au sein du conseil. La durée de 10 ans des options assure une alignement à long terme avec les intérêts des actionnaires.

Die Form 4-Meldung zeigt, dass Anthony Gregg Lapointe, Direktor von Soligenix, am 20. Juni 2025 eine Aktienoptionszuteilung erhalten hat. Die Details der Derivat-Transaktion umfassen:

  • Gewährung von 17.647 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis von 1,70 $ pro Aktie
  • Optionen verfallen am 20. Juni 2035
  • Vesting erfolgt in vier gleichen Tranchen: - 20. September 2025 - 20. Dezember 2025 - 20. März 2026 - 20. Juni 2026

Diese Zuteilung stellt eine übliche Vergütung für Direktoren dar und zeigt ein fortgesetztes Engagement im Vorstand. Die 10-jährige Optionslaufzeit sorgt für eine langfristige Ausrichtung an den Interessen der Aktionäre.

Positive
  • None.
Negative
  • None.

La comunicazione del modulo 4 rivela che Anthony Gregg Lapointe, Direttore di Soligenix, ha ricevuto una concessione di stock option il 20 giugno 2025. I dettagli della transazione sui titoli derivati includono:

  • Concessione di 17.647 stock option per l'acquisto di azioni ordinarie
  • Prezzo di esercizio fissato a 1,70 $ per azione
  • Le opzioni scadono il 20 giugno 2035
  • Il piano di maturazione avviene in quattro rate uguali: - 20 settembre 2025 - 20 dicembre 2025 - 20 marzo 2026 - 20 giugno 2026

Questa concessione rappresenta una compensazione standard per i direttori e indica un continuo impegno nel consiglio di amministrazione. Il termine decennale delle opzioni assicura un allineamento a lungo termine con gli interessi degli azionisti.

La presentación del Formulario 4 revela que Anthony Gregg Lapointe, Director de Soligenix, recibió una concesión de opciones sobre acciones el 20 de junio de 2025. Los detalles de la transacción con valores derivados incluyen:

  • Otorgamiento de 17,647 opciones sobre acciones para comprar acciones comunes
  • Precio de ejercicio establecido en $1.70 por acción
  • Las opciones expiran el 20 de junio de 2035
  • El calendario de adquisición se realiza en cuatro cuotas iguales: - 20 de septiembre de 2025 - 20 de diciembre de 2025 - 20 de marzo de 2026 - 20 de junio de 2026

Esta concesión representa una compensación estándar para directores e indica un compromiso continuo con el consejo. El plazo de 10 años de las opciones proporciona una alineación a largo plazo con los intereses de los accionistas.

Form 4 제출서에 따르면 Anthony Gregg Lapointe 솔리제닉스 이사가 2025년 6월 20일에 스톡옵션을 부여받았습니다. 파생증권 거래 내역은 다음과 같습니다:

  • 17,647주의 보통주 매수 옵션 부여
  • 행사가격은 주당 $1.70
  • 옵션 만료일은 2035년 6월 20일
  • 옵션 권리 확정은 4회에 걸쳐 동일한 비율로 이루어짐: - 2025년 9월 20일 - 2025년 12월 20일 - 2026년 3월 20일 - 2026년 6월 20일

이번 부여는 이사 보상으로 일반적인 수준이며, 이사회 참여가 지속됨을 나타냅니다. 10년 만기 옵션은 주주 이익과 장기적으로 일치하도록 설계되었습니다.

Le dépôt du formulaire 4 révèle que Anthony Gregg Lapointe, administrateur de Soligenix, a reçu une attribution d'options d'achat d'actions le 20 juin 2025. Les détails de la transaction sur titres dérivés sont les suivants :

  • Attribution de 17 647 options d'achat pour acquérir des actions ordinaires
  • Prix d'exercice fixé à 1,70 $ par action
  • Les options expirent le 20 juin 2035
  • Le calendrier d'acquisition s'effectue en quatre versements égaux : - 20 septembre 2025 - 20 décembre 2025 - 20 mars 2026 - 20 juin 2026

Cette attribution représente une rémunération standard pour les administrateurs et témoigne d'un engagement continu au sein du conseil. La durée de 10 ans des options assure une alignement à long terme avec les intérêts des actionnaires.

Die Form 4-Meldung zeigt, dass Anthony Gregg Lapointe, Direktor von Soligenix, am 20. Juni 2025 eine Aktienoptionszuteilung erhalten hat. Die Details der Derivat-Transaktion umfassen:

  • Gewährung von 17.647 Aktienoptionen zum Kauf von Stammaktien
  • Ausübungspreis von 1,70 $ pro Aktie
  • Optionen verfallen am 20. Juni 2035
  • Vesting erfolgt in vier gleichen Tranchen: - 20. September 2025 - 20. Dezember 2025 - 20. März 2026 - 20. Juni 2026

Diese Zuteilung stellt eine übliche Vergütung für Direktoren dar und zeigt ein fortgesetztes Engagement im Vorstand. Die 10-jährige Optionslaufzeit sorgt für eine langfristige Ausrichtung an den Interessen der Aktionäre.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LAPOINTE ANTHONY GREGG

(Last) (First) (Middle)
C/O SOLIGENIX, INC.
29 EMMONS DRIVE, SUITE B-10

(Street)
PRINCETON NJ 08540

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SOLIGENIX, INC. [ SNGX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/20/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $1.7 06/20/2025 A 17,647 (1) 06/20/2035 Common Stock 17,647 $0 17,647 D
Explanation of Responses:
1. The stock option vests ratably on each of September 20, 2025, December 20, 2025, March 20, 2026 and June 20, 2026.
/s/ Gregg A. Lapointe 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did SNGX director Anthony Lapointe receive on June 20, 2025?

Director Anthony Lapointe received 17,647 stock options with an exercise price of $1.70 per share. These options were granted on June 20, 2025, and will expire on June 20, 2035.

What is the vesting schedule for SNGX director Lapointe's stock options granted in June 2025?

The stock options vest in four equal installments on: September 20, 2025, December 20, 2025, March 20, 2026, and June 20, 2026.

How long can Anthony Lapointe exercise his SNGX stock options granted in June 2025?

The stock options have a 10-year term, with an expiration date of June 20, 2035.

What is the exercise price of SNGX stock options granted to director Lapointe in June 2025?

The exercise price of the stock options is $1.70 per share.

How many SNGX stock options does Anthony Lapointe beneficially own after the June 2025 grant?

Following the reported transaction, Anthony Lapointe beneficially owns 17,647 stock options directly (Form D).
Soligenix Inc

NASDAQ:SNGX

SNGX Rankings

SNGX Latest News

SNGX Latest SEC Filings

SNGX Stock Data

5.39M
3.15M
0.03%
1.22%
4.01%
Biotechnology
Pharmaceutical Preparations
Link
United States
PRINCETON